Get access to our best features

Get access to our best features

Moderna, Merck's mRNA cancer vaccine, Keytruda combo gets FDA breakthrough therapy tag

Summary by Ground News
Moderna and Merck's personalized mRNA cancer vaccine mRNA-4157/V940, in combination with Keytruda, for the adjuvant treatment of patients with high-risk melanoma after complete resection. FDA's decision was backed by data from a phase 2b trial, dubbed KEYNOTE-942/mRNA- 4157-P201.
Published 3 months ago

News Articles

More Filters
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

67% of the sources lean Right
Seeking Alpha
C 33%
R 67%
See less detail